Skip to content

Enliven Therapeutics ELVN Return on invested capital

Return on invested capital at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
13%+4.2pp
Pfizer logo
PfizerPFE
6%
Arcus Biosciences logo
Arcus BiosciencesRCUS
-95.3%+1.8pp
Iovance Biotherapeutics, Inc. logo
Iovance Biotherapeutics, Inc.IOVA
-59.5%-2.6pp
Immunome logo
ImmunomeIMNM
-746.6%+212pp
Nuvation Bio logo
Nuvation BioNUVB
-47.4%-18.6pp

Other financials

Income statement

See full
Operating income-$27.8M+12.2%
Net income-$23.6M+17.2%
EPS (diluted)-$0.38+33.3%

Balance sheet

See full
Cash & equivalents$132.2M+30.0%
Total debt$302.0K-56.9%
Total equity$453.4M+57.3%
Total assets$464.9M+53.6%

Cash flow

See full
Operating cash flow-$19.3M+20.0%
CapEx--100%
Free cash flow-$19.3M+20.1%

Valuation

See full
Market cap$3.47B+143%
Enterprise value$3.34B+156%

Returns & leverage

See full
Return on equity-26.6%-3.5pp
Debt / equity0.0×
Current ratio40.3×+19.3×

Where this comes from

Calculated from Enliven Therapeutics’s reported figures.

Based on trailing twelve months.

The official record: Enliven Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Enliven Therapeutics's return on invested capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Enliven Therapeutics's return on invested capital?
Enliven Therapeutics (ELVN) reported return on invested capital of -45.5% in Q1 2026.
How has Enliven Therapeutics's return on invested capital changed year-over-year?
Enliven Therapeutics's return on invested capital increased by 26.5% year-over-year, from -61.9% to -45.5%.
What does return on invested capital mean?
Net operating profit after tax (operating income taxed at the effective rate) divided by average invested capital (debt plus equity minus cash). Measures the after-tax return on all capital put to work in the business, independent of capital structure.